Artelo Biosciences, Inc.

Stage 4 · Declining · week 24

As of Oct 22, 2026, Artelo Biosciences is in Stage 4, the downtrend phase, now in week 24 (since May 7, 2026). It closed at $2.55, 97.3% below its 52-week high and below its 200-day average, which is falling.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. More about the company

$2.55

-3.77% today

$1.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ARTL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S1 14w

S4 40w

S4 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 3w → S4 19w → S1 14w → S4 40w → S1 6w → S4 11w → S1 4w → S2 10w → S3 3w → S4 24w → S1 6w → S4 24w current

Total tracked: 166 weeks across 12 stage runs.

ARTL among Biotechnology535th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…535	ARTLArtelo Biosciences, Inc.	Stage 4 · wk 24	4	−65.1%

vs 52W High

-97.3%

$2.55 lo$95.85 hi

97.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 24

1w13w26w

Week 24, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-88.9%

200 DMA: $22.93 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.02x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-65.1%

-72.2%

-92.9%

YTD

-92.6%

-97.3%

Scan Membership

Breakout Watch

Latest: 2021-02-17

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 24 · Vol 0.02x

2026-10-21S4

Wk 24 · Vol 0.03x

2026-10-20S4

Wk 23 · Vol 0.04x

2026-10-19S4

Wk 23 · Vol 0.03x

2026-10-16S4

Wk 23 · Vol 0.02x

2026-10-15S4

Wk 23 · Vol 0.03x

2026-10-14S4

Wk 23 · Vol 0.07x

2026-10-13S4

Wk 22 · Vol 0.05x

2026-10-12S4

Wk 22 · Vol 0.04x

2026-10-09S4

Wk 22 · Vol 0.07x

2026-10-08S4

Wk 22 · Vol 0.04x

2026-10-07S4

Wk 22 · Vol 0.08x

Moving averages & range

50 DMA

$4.81

200 DMA

$22.93

52W High

$95.85

52W Low

$2.55

5D Low

$2.55

Resistance levels (recent highs)

20d High

$4.54

60d High

$7.31

120d High

$29.70

250d High

$95.85

Next resistance

+78.0%

to 20d High

ROE

-705.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

Artelo Biosciences: quick answers

What stage is Artelo Biosciences in?

As of Oct 22, 2026, Artelo Biosciences (ARTL) is in Stage 4, the downtrend phase. It entered Stage 4 on May 7, 2026 and is in week 24. What the four stages mean

Is Artelo Biosciences in an uptrend?

No. Artelo Biosciences is in a Stage 4 downtrend. It trades 88.9% below its 200-day average, which is falling.

How far is Artelo Biosciences from its 52-week high?

Artelo Biosciences closed at $2.55 on Oct 22, 2026, 97.3% below its 52-week high of $95.85. Its 52-week low is $2.55.

How has Artelo Biosciences performed over the past year?

As of Oct 22, 2026, Artelo Biosciences is down 97.3% over the past year and down 92.6% so far in 2026.

Which sector and industry is Artelo Biosciences in?

Artelo Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.